Why Invest?
Milestones
2008
April
- Results from Isotechnika's Canadian Phase 3 psoriasis trial published in The Lancet
March
- An independent data monitoring committee (DMC) conducts review of blinded Phase 3 European/Canadian psoriasis trial (ESSENCE) safety and efficacy data. The DMC did not raise any concerns that would require a change to the original study design.
- ISA247 issued generic name, voclosporin
January
- Last patient enrolled in voclosporin Phase 2b kidney transplant trial completes six month treatment
2007
December
- Swedish Patent issued for mTOR inhibitor, TAFA93
November
- Rat carcinogenicity study for voclosporin completed
- Norwegian Patent 32402 issued for voclosporin
August
- EMEA recommends Orphan Medicinal Product Designation for voclosporin in uveitis
- Food and Drug Administration allows patients who have already completed 12 months of voclosporin treatment to continue therapy through to commercialization of the drug
- FDA grants Fast-Track designation for voclosporin for the treatment of uveitis
July
- Completion of recruitment in Phase 3 ESSENCE trial
June
- Health Canada grants Isotechnika No Objection Letter allowing patients who have already completed 12 months of voclosporin treatment to continue therapy through to commercialization of the drug
- Isotechnika achieves full enrolment for voclosporin Phase 2b kidney transplant trial
May
- Health Canada grants Isotechnika's partner, Lux Biosciences, No Objection Letter to investigate voclosporin in Phase 2/3 clinical trials for treatment of uveitis
- Isotechnika hosts educational symposium at American Transplant Congress
March
- Isotechnika receives USAN approval to generic name for voclosporin
February
- Isotechnika's partner, Lux Biosciences, initiates pivotal trials in uveitis for voclosporin
- Isotechnika completed bought deal financing for total proceeds of $40.2 million
January
- Isotechnika's partner, Lux Biosciences, is granted orphan drug designation from Food and Drug Administration for voclosporin, referred to as LX211 by Lux
2006
December
- Isotechnika enrols first patient in European/Canadian Phase 3 psoriasis trial
November
- Isotechnika's lead drug, voclosporin, positioned to enter clinical trials for uveitis
- Isotechnika receives Notice of Allowance for mTOR inhibitor, TAFA93
- Isotechnika announces promising initial data from Phase 2b kidney transplant trial
October
- Isotechnika successfully completes a Canadian Phase 3 psoriasis trial
- Isotechnika receives European Patent No. EP0991660 for voclosporin
August
- Isotechnika announces promising results from TAFA93 Phase 1 trials
June
- Isotechnika is granted U.S. Patent No. 7,060,072 for voclosporin
May
- Isotechnika signs agreement granting Lux Biosciences worldwide ophthalmic rights to voclosporin
April
- Isotechnika signs option agreement for topical delivery technology of voclosporin
March
- Isotechnika announces preliminary 48 week clinical data from the Phase 3 voclosporin psoriasis trial
February
- Isotechnika receives additional US patent for lead immunosuppressive drug voclosporin
January
- Isotechnika enrolls first patient in Phase 2b kidney transplant trial
2005
- Isotechnika announces Nine Month Safety Data from the Phase 3 psoriasis trial for voclosporin
- Isotechnika's Phase 3 psoriasis SPIRIT trial achieves safety and efficacy endpoints
- Isotechnika and Atrium Medical announce licensing agreement for use of TAFA93 and voclosporin with medical devices
- Isotechnika's Phase 3 psoriasis trial achieves clinical endpoints
- Isotechnika announces 90% participation in Phase 3 psoriasis extension trial
- Isotechnika announces interim blinded results for voclosporin Canadian Phase 3 psoriasis trial
- Isotechnika granted Moroccan Patent No. 27293 for "Synthesis of Cyclosporin Analogs"
- Isotechnika granted permission from Food and Drug Administration (FDA) for Phase 2b kidney transplant trial
- Isotechnika receives No Objection Letter from Health Canada to conduct a Phase 2b kidney transplant trial
- Isotechnika announced promising preliminary Phase 3 psoriasis results
- Isotechnika's Helikit diagnostic test was added to insured health service list in Alberta
- Isotechnika granted US Patent 6,878,550 for its diagnostic breath test kit, Diatest
- Isotechnika achieves target enrolment for voclosporin Canadian Phase 3 psoriasis trial
2004
- Isotechnika initiates voclosporin Canadian Phase 3 psoriasis trial after receiving a No Objection Letter from Health Canada
- Trans-voclosporin multiple ascending dose study achieves all endpoints
- Trans-voclosporin QTC trial, food effect study and bioequivalence study successfully completed
- Isotechnika acquires breath kit manufacturing business
- Isotechnika is granted permission for TAFA93 Phase 1b clinical trial
- Isotechnika receives permission from Health Canada for Phase 1a clinical trial for TAFA93
- Isotechnika receives positive data from trans-voclosporin single ascending dose trial
- Isotechnika reacquires the world-wide rights for all non-transplant indications for voclosporin
- Isotechnika receives regulatory approval for Helikit in China
- Manufacturing process finalized for voclosporin
- Isotechnika granted U.S. Patent No. 6,686,454 for voclosporin
- Diatest results published in Diabetes Care publication
- Isotechnika places third on Alberta's 2003 Fasting Growing Companies list
2003
- Isotechnika announces the addition of TKB662 to its immunosuppressive pipeline
- Isotechnika receives U.S. Patent for voclosporin
- Isotechnika completes $15,000,000 US private placement
- Isotechnika releases final results of Phase 2a kidney transplant trial at American Transplant Congress
- Announcement of new immunosuppressive drug candidate, TAFA93
- Isotechnika earns $21,900,000 CDN drug development milestone payment
- Isotechnika releases final results of Phase 2 psoriasis trial
2002
- Isotechnika opens new state-of-the-art lab facilities in Edmonton, Canada
- Completion of patient recruitment for voclosporin Phase 2 clinical trial in Psoriasis
- Isotechnika and Roche sign largest drug development agreement in Canadian history
2001
- Isotechnika receives Canadian Patent for voclosporin
- Isotechnika receives New Zealand Patent for voclosporin
- Isotechnika is listed on the TSE300
- Subsidiary, Isodiagnostika, begins selling diabetes breath test kit after receiving approval from Health Canada
- Isotechnika expands into United States, opening an office in Arizona
- Isotechnika receives U.S. Patent for Novel Treatment of Cancer
- Voclosporin trials of kidney transplant patients begin at twelve (12) North American centres (including the University of Alberta, Dalhousie University and Stanford University)
- Health Canada gives approval for Phase 2 trials of voclosporin in rheumatoid arthritis and psoriasis patients
- TD Securities led syndicate close $25 million warrant deal
- The Food and Drug Administration and Health Canada give speedy approval for Phase 2 trials of kidney transplant patients
2000
- Subsidiary, Isodiagnostika, granted European approval for the sale of its breath based test kit, Helikit
- Isotechnika listed on the Toronto Stock Exchange; shares increase roughly 300 % from the IPO
- Isotechnika completes Phase 1 human clinical trials in 8 months
1998
- Isotechnika goes public on the Alberta Stock Exchange; the IPO is set at $1.25
1997
- Isotechnika discovers voclosporin, a drug to replace cyclosporine; twenty-two separate tests prove it's 500% more potent then cyclosporine without demonstrating any significant toxic side effects
1993-95
- Company focuses on contract work for international drug companies
- Isotechnika joins a world search for a drug to replace cyclosporine
1993
- University of Alberta Pharmacy Professor, Dr. Robert Foster, and a colleague launch Isotechnika
Last updated April 24, 2008